ProKidney Corp. (NASDAQ:PROK) Insider Control Empresarial De Capital Acquires 100,000 Shares

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital bought 100,000 shares of the business’s stock in a transaction on Wednesday, April 16th. The stock was bought at an average price of $0.75 per share, for a total transaction of $75,000.00. Following the transaction, the insider now directly owns 73,430,330 shares of the company’s stock, valued at approximately $55,072,747.50. This represents a 0.14 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Control Empresarial De Capital also recently made the following trade(s):

• On Monday, April 14th, Control Empresarial De Capital bought 268,105 shares of ProKidney stock. The stock was purchased at an average cost of $0.73 per share, with a total value of $195,716.65.
• On Thursday, April 10th, Control Empresarial De Capital acquired 1,032,218 shares of ProKidney stock. The stock was purchased at an average cost of $0.61 per share, with a total value of $629,652.98.

ProKidney Trading Down 0.6 %

NASDAQ:PROK traded down $0.01 during mid-day trading on Friday, hitting $0.79. 1,018,709 shares of the company’s stock were exchanged, compared to its average volume of 687,286. ProKidney Corp. has a fifty-two week low of $0.46 and a fifty-two week high of $4.44. The firm has a market capitalization of $231.49 million, a P/E ratio of -1.44 and a beta of 1.52. The company has a 50 day simple moving average of $1.03 and a 200-day simple moving average of $1.51.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.08 million for the quarter. As a group, analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On ProKidney

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in ProKidney by 102.0% in the third quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company’s stock valued at $4,232,000 after acquiring an additional 1,112,933 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of ProKidney during the fourth quarter worth $961,000. JPMorgan Chase & Co. raised its stake in ProKidney by 65.1% during the third quarter. JPMorgan Chase & Co. now owns 46,830 shares of the company’s stock worth $90,000 after buying an additional 18,472 shares during the last quarter. State Street Corp raised its stake in ProKidney by 16.2% during the third quarter. State Street Corp now owns 1,428,318 shares of the company’s stock worth $2,742,000 after buying an additional 198,836 shares during the last quarter. Finally, Barclays PLC lifted its holdings in ProKidney by 575.7% in the third quarter. Barclays PLC now owns 146,321 shares of the company’s stock valued at $281,000 after buying an additional 124,667 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.